Patricia Inácio, PhD, science writer —

Amgen is seeking to expand the approval of its proteasome inhibitor Kyprolis (carfilzomib) in the U.S. to include once-weekly dosing combined with dexamethasone for multiple myeloma patients with hard-to-treat disease or whose disease relapsed. The company used data from its Phase 3 ARROW trial as the basis for its…

The U.S. Food and Drug Administration granted priority review to Bristol-Myers Squibb’s supplemental Biologics License Application (sBLA) for Empliciti (elotuzumab) combined with Pomalyst (pomalidomide) and low-dose dexamethasone as a treatment for patients with relapsed or treatment-resistant multiple myeloma. The application covers patients whose disease has progressed despite treatment with at least two…

The U.S. Food and Drug Administration has granted orphan drug status to SRF231 to treat multiple myeloma, according to Surface Oncology, which is developing the investigational therapy. Orphan drug designation aims to assist in developing therapies for rare and serious diseases that have a high unmet need by providing…

Expanded use of Darzalex (daratumumab) in combination with standard therapy for treating adult patients with newly-diagnosed multiple myeloma, and who are not candidates for stem cell transplant, has been recommended by the European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP). The recommendation is based on results from the…

Takeda‘s proteasome inhibitor Ninlaro (ixazomib) prevents multiple myeloma from progressing or returning when given as a maintenance therapy to patients who responded to first-line therapy and stem cell transplant, a Phase 3 clinical trial shows. The trial, called TOURMALINE-MM3 (NCT02181413), compared Ninlaro to placebo in newly-diagnosed patients given standard induction therapy…

Adding Empliciti (elotuzumab) to a combination of Pomalyst (pomalidomide) and dexamethasone significantly delays disease worsening or death in myeloma patients who failed to respond to previous treatment, data from the Phase 2 ELOQUENT-3 trial show. These results were recently shared at the 23rd European Hematology Association (EHA) Congress in Stockholm, in a presentation titled…

While the best described cancer mutations are in regions that provide instructions to make proteins, most mutations actually happen in the noncoding regions of our genome, researchers found. University of California researchers identified 200 new mutations in noncoding DNA that drive tumor formation and growth. Their findings may lead to…

Updated clinical trial data show that selinexor added to standard therapies can benefit multiple myeloma patients who have failed multiple prior lines of therapy, Karyopharm Therapeutics announced. This data — from the ongoing Phase 1b/2 STOMP (NCT02343042) trial — was presented in three posters at the European Hematology Association (EHA) annual…

The investigational cancer vaccine galinpepimut-S (GPS) has been designated an orphan drug by the U.S. Food and Drug Administration as a possible treatment of multiple myeloma, Sellas Life Sciences announced. The FDA’s orphan drug designation is expected to support and expedite the clinical development and regulatory review…

The supervised use of medicinal cannabis is safe and effective at relieving pain and reducing chemotherapy-induced nausea and vomiting in cancer patients, an increasing body of research data shows. In a new feature issue of the European Journal of Internal Medicine, researchers revised the current data on cannabis and derived products…